Actavis plc has opened  its new regional office in Singapore that will serve as the headquarters for the company’s Asia Pacific and Africa (APACA) region. In addition, Actavis announced that its subsidiary operating in Singapore—Drug Houses of Australia Pte Ltd (DHA —will be transitioned to the Actavis brand. 

“The opening of our new regional headquarters in Singapore is an important step in Actavis’ global expansion and further evidence of our commitment to being a leading provider of a full range of pharmaceutical products in the region,” said Paul Bisaro , chairman and CEO of Actavis, in a press statement. “By centralizing our regional operations in Singapore, we will be better positioned to focus on strategies that will strengthen our growth in emerging markets across Southeast Asia, enabling consumers to have increased access to affordable, high-quality medicines that help them live longer, healthier lives.”

Actavis’ DHA business offers a portfolio of pharmaceuticals, including generics, brands and over-the-counter (OTC) products. The company also operates a manufacturing facility in Singapore, producing a range of products in various formulations, including tablets, capsules, oral solutions, dry suspensions, ointments, and liniments. In total, Actavis employs more than 130 people in Singapore.

Source: Actavis